Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes
-
Published:2024-02
Issue:2
Volume:42
Page:225-237.e5
-
ISSN:1535-6108
-
Container-title:Cancer Cell
-
language:en
-
Short-container-title:Cancer Cell
Author:
Heeke SimonORCID, Gay Carl M., Estecio Marcos R., Tran Hai, Morris Benjamin B., Zhang Bingnan, Tang Ximing, Raso Maria Gabriela, Rocha Pedro, Lai Siqi, Arriola Edurne, Hofman Paul, Hofman Veronique, Kopparapu Prasad, Lovly Christine M., Concannon Kyle, De Sousa Luana Guimaraes, Lewis Whitney Elisabeth, Kondo Kimie, Hu Xin, Tanimoto Azusa, Vokes Natalie I., Nilsson Monique B., Stewart Allison, Jansen Maarten, Horváth Ildikó, Gaga Mina, Panagoulias Vasileios, Raviv Yael, Frumkin Danny, Wasserstrom Adam, Shuali Aharona, Schnabel Catherine A., Xi Yuanxin, Diao Lixia, Wang Qi, Zhang Jianjun, Van Loo Peter, Wang Jing, Wistuba Ignacio I., Byers Lauren A., Heymach John V.
Reference77 articles.
1. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer;Horn;N. Engl. J. Med.,2018 2. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial;Paz-Ares;Lancet,2019 3. Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small cell lung cancer (SCLC);Byers;J. Clin. Oncol.,2019 4. A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer;Hipp;Clin. Cancer Res.,2020 5. Tarlatamab, a First-In-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small Cell Lung Cancer: An Open-Label, Phase I Study;Paz-Ares;J. Clin. Oncol.,2023
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|